GI Oncology Papers’ Post

Patients with HR+, HER2– early breast cancer are at high risk of recurrence and need intensification of treatment. At the pivotal 5-year mark for adjuvant EBC trials, adjuvant abemaciclib plus endocrine therapy continued to reduce the risk of developing invasive and distant disease recurrence well beyond the completion of treatment. This infographic reviews 5-year efficacy results of adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- EBC. Download your copy: https://ow.ly/OTna50TNyUb #BreastCancer #OncoAlert #MedOnc #OncEd

Revolutionize your CRC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions and alleviate patient anxiety*! Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy. Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay.  👉 Read more https://lnkd.in/ew295pPq Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #MSI #RAS #NRAS #KRAS #BRAF #immunotherapy #ColorectalCancer #CRC *Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.

#ClinicalMonday Promising Results in Cancer Treatment: A New Standard for Nasopharyngeal Carcinoma 🔬 Exciting news from a recent Phase 3 clinical trial comparing chemotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma (NPC) reveals a promising new standard of care! 💊 Nab-paclitaxel, cisplatin, and capecitabine (nab-TPC) demonstrated significantly better outcomes than the traditional gemcitabine-cisplatin regimen: ✅ Progression-Free Survival: Extended from 7.7 to 11.3 months ✅ Response Rate: 83% for nab-TPC vs. 63% for gemcitabine-cisplatin ✅ Longer Duration of Response: 10.8 vs. 6.9 months ✅ Fewer Side Effects: Lower rates of severe leukopenia, neutropenia, and anemia ✅ No Treatment-Related Deaths With these positive results, nab-TPC could become the first-line treatment for recurrent/metastatic NPC, offering patients extended progression-free survival and improved safety. 💬 Read more: https://lnkd.in/gANYpScX Stay tuned for more updates as we follow the long-term impacts of this revolutionary treatment! #CancerResearch #ClinicalTrials #NasopharyngealCarcinoma #OncologyInnovation #HealthcareTransformation Image source: medtour.help

This November, the Society for Immunotherapy of Cancer (SITC) honors the vital role of #familycaregivers in supporting the quality of life (QOL) of patients living with cancer. To help improve QOL for these patients, SITC clinical practice guidelines often provide evidence- and consensus-based recommendations on QOL support and patient/caregiver education related to cancer immunotherapy treatments. These recommendations can help physicians, patients, and caregivers understand important QOL considerations. Learn more about SITC CPGs here: https://ow.ly/WI7F50U4nW3 #NationalFamilyCaregiversMonth #NFCMonth #QOL

📢 New Publication Alert! 🚨 We're excited to share our latest systematic review exploring novel regimens and treatment strategies in neoadjuvant therapy (NACT) for colorectal cancer (CRC)! In this comprehensive analysis, we dove deep into the latest advancements in NACT, covering: 🔹 Cytotoxic drugs 🔹 Targeted therapies 🔹 Immunotherapy approaches Our findings highlight the potential benefits and challenges of these novel therapies and the critical need for further research to optimize NACT use and improve outcomes for CRC patients. The evolution of neoadjuvant strategies is reshaping treatment paradigms, opening doors to more precise, personalized care. Check out the article for insights into the future of CRC treatment and the exciting prospects for precision medicine and immunotherapy in clinical practice! Link: https://lnkd.in/dxG6qXsT #ColorectalCancer #NeoadjuvantTherapy #CancerResearch #Oncology #PrecisionMedicine #Immunotherapy #ClinicalTrials #SystematicReview

Revolutionize your CRC diagnostics with Idylla™ 🏆  ⏱️Speed up your therapy decisions and alleviate patient anxiety*! Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy. Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay. 👉 Read more https://lnkd.in/eB8vgaVE Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #MSI #RAS #NRAS #KRAS #BRAF #immunotherapy #ColorectalCancer #CRC *Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.

Exciting News for our community! A Phase 2 study has just started evaluating ulixertinib, a first-in-class ERK 1/2 inhibitor being developed by Biomed Valley Discoveries, for treating histiocytosis. This rare disorder causes abnormal white blood cell growth, leading to serious health issues. Dr. Eli Diamond from Memorial Sloan Kettering Cancer Center leads this study, building on promising results from patients who previously tried ulixertinib. This new approach could offer a breakthrough for those who don't respond to current treatments. We are hopeful that ulixertinib will bring a much-needed new treatment option for histiocytosis patients! Learn more about this exciting development by clicking this link: https://lnkd.in/enPPCnBT #Histiocytosis #Ulixertinib #BiomedValleyDiscoveries #NewHope #CancerResearch #ClinicalTrials #PatientCare #MedicalBreakthrough

𝐂𝐨𝐮𝐥𝐝 𝐅𝐑𝐔𝐙𝐀𝐐𝐋𝐀™ 𝐫𝐞𝐝𝐞𝐟𝐢𝐧𝐞 𝐦𝐂𝐑𝐂 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭? Takeda's new release, #FRUZAQLA, marks a pivotal shift in metastatic colorectal cancer care. As the first oral therapy targeting all three VEGF receptor kinases, it promises a novel approach for patients who have exhausted other options. The edge? FRUZAQLA™ demonstrated significant gains in both overall and progression-free survival against placebos in Phase 3 trials. This is a new direction for patient care. Why pivot to FRUZAQLA™ now? It offers a chemotherapy-free alternative, crucial for enhancing quality of life in mCRC treatments. This positions FRUZAQLA™ not just as a medication, but as a cornerstone in modern oncology strategies. How will FRUZAQLA™ fit into your current treatment landscape? Share your thoughts! 𝐏.𝐒. 𝐃𝐨𝐧'𝐭 𝐟𝐨𝐫𝐠𝐞𝐭 𝐭𝐨 𝐫𝐞𝐩𝐨𝐬𝐭 ♻️ 𝐭𝐡𝐢𝐬 𝐟𝐨𝐫 𝐨𝐭𝐡𝐞𝐫𝐬. #Cancer #Oncology #Oncolyst #ColorectalCancer 𝐍𝐨𝐭𝐞: This is for education purpose. Please consult your doctor before opting for any treatment.

In a significant advance for hepatocellular carcinoma (HCC) treatment, a network meta-analysis published examines the effectiveness of atezolizumab combined with bevacizumab. Assessing 16 clinical studies with over 8,700 subjects, this analysis found that the combination therapy notably improves overall survival (OS) and progression-free survival (PFS) for patients with advanced HCC. This groundbreaking therapy represents a substantial leap in first-line systemic treatments, offering a new beacon of hope for patients battling this challenging disease. The study advocates for the adoption of this combination therapy in clinical practice, marking a pivotal moment in cancer treatment. #ClinicalOutcomes #CancerBreakthrough #PatientCareAdvances

#sponsored Are you making an informed decision for you regarding extending endocrine (anti-estrogen) therapy past the 5-year mark? If you are on endocrine therapy for early-stage, Hormone Receptor-Positive (HR+) breast cancer, the Breast Cancer Index test (BCI) predicts if you are likely to benefit from endocrine therapy past year 5. New data shows that 45% of women changed their preference for extended endocrine therapy following BCI results, and 41% felt more comfortable with their decision. BCI provides valuable information to help guide treatment decisions, so you and your healthcare team can feel more confident in your path forward. I encourage you to use all the technologies we as breast cancer survivors now have available to make the most informed, personalized treatment decisions with your healthcare team. Learn more in my recent blog: https://lnkd.in/gbbNMr5b #breastcancerindex #findyourfinish @Hologic @breastcancerindex #breastcancersurvivor #5yearmark #antiestrogentherapy